SGLT2 Inhibitors Tied To Uptick In Hemoglobin And Hematocrit

TL;DR

For listenersOffer from Amazon

Turn your wind-down time into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

A meta-analysis of 85 randomized trials involving 70,543 participants found that SGLT2 inhibitor treatment was associated with higher hemoglobin and hematocrit than control treatment over a median of 24 weeks. Researchers said the accompanying changes in erythropoietin and iron-related measures point beyond simple fluid loss, but the trials did not establish whether the blood changes improve anemia or cause the drugs’ cardiorenal benefits.

A meta-analysis of 85 randomized trials found that SGLT2 inhibitors were associated with modest but statistically significant increases in hemoglobin and hematocrit across a range of patient groups, including people with chronic kidney disease, heart failure and type 2 diabetes. The findings, presented at the American Society of Nephrology Kidney Week meeting and published in JAMA, describe changes in blood measures; they do not establish that the drugs treat anemia or that those changes cause their known health benefits.

The analysis included 70,543 participants and followed patients for a median of 24 weeks. Hemoglobin rose by an average of 0.55 g/dL in SGLT2 inhibitor groups, while it fell by 0.08 g/dL in control groups. The between-group difference was 0.60 g/dL (95% confidence interval 0.55 to 0.66; P<0.001).

Hematocrit increased by 2.17% in the treatment groups and declined by 0.13% in controls, a between-group difference of 2.36 percentage points (95% confidence interval 2.19 to 2.52; P<0.001). The trials covered participants with chronic kidney disease, heart failure, type 2 diabetes, cardiovascular disease, or combinations of those conditions.

Among secondary measures, the researchers reported higher erythropoietin and red blood cell concentrations, alongside lower ferritin and transferrin saturation, in treatment groups than in control groups. Changes in hepcidin and serum iron did not reach statistical significance. The authors said the overall pattern is consistent with changes in red blood cell production and iron metabolism, but the available trial data do not directly establish the biological mechanism.

Potential Relevance to Anemia Care

The results may matter for patients with chronic kidney disease or heart failure, conditions in which anemia can be a concern. In their accompanying editorial, Kai-Uwe Eckardt of Charité-Universitätsmedizin Berlin and Mark J. Koury of Vanderbilt University Medical Center wrote that a modest hemoglobin rise could contribute to anemia management. That is a potential implication, not evidence that SGLT2 inhibitors can replace established anemia treatments.

The authors also noted that elevated starting hemoglobin or hematocrit could make additional increases a safety consideration, including a possible risk of thromboembolic events. The meta-analysis does not establish that the observed changes caused such events or quantify any added risk. Clinicians and patients should not infer an individual treatment decision from these group-level results alone.

Understanding the mechanism could also clarify whether changes in blood production help explain previously reported quality-of-life improvements or cardiorenal outcomes. The researchers said further trials are needed to test whether the hematologic changes directly contribute to those benefits or reduce the need for conventional anemia treatments.

What the Trials Measured

The review screened double-blind randomized trials in which SGLT2 inhibitors were used alone or added to other treatment. Participants had a mean age of 62.4 years; 35.9% were female. Average baseline hemoglobin was 13.6 g/dL, and average hematocrit was 41.5%. Most trials studied empagliflozin or dapagliflozin, with other SGLT2 inhibitors also represented.

Earlier explanations for higher hemoglobin and hematocrit focused mainly on hemoconcentration—a higher concentration of blood components as fluid levels change. The meta-analysis authors pointed to higher erythropoietin and lower ferritin and transferrin saturation as evidence consistent with a broader effect on red blood cell production and iron handling. The editorial authors noted that hemoglobin reached its maximum increase at 48 weeks in prior observations, which they said may fit gradual adjustment of blood-cell production rather than sustained fluid contraction.

Post hoc analyses in the report suggested larger hemoglobin differences at higher doses and longer follow-up. Those analyses found a 0.65 g/dL difference at 1.5 times the standard clinical dose and a 0.71 g/dL difference at 48 weeks. They are exploratory findings and do not by themselves establish how dose or treatment duration should be chosen.

“This is the largest and most comprehensive analysis to date of the effects of SGLT2 inhibitors on hematologic and iron-related parameters.”

— Michele F. Eisenga, MD, PhD, University Medical Center Groningen

Mechanism and Safety Questions

The trials included in the analysis had limited data on red blood cell indices. They did not report measurements of red blood cell mass, plasma volume or red blood cell lifespan, the editorial authors said. Without those assessments, the increase in hemoglobin and hematocrit cannot be conclusively attributed to greater red blood cell mass rather than other processes.

It also remains unclear whether these changes directly improve anemia, contribute to cardiorenal benefits, or affect the need for existing anemia treatments. The report raises a possible concern for people whose hemoglobin or hematocrit is already high, but it does not quantify thromboembolic risk attributable to treatment. The findings show average changes across trials, not how an individual patient will respond.

Evidence Needed From Future Trials

The researchers said future trials should test whether changes in hemoglobin and related measures contribute directly to the cardiorenal benefits associated with SGLT2 inhibitors and whether treatment reduces reliance on conventional anemia therapies. Studies measuring red blood cell mass, plasma volume and cell lifespan could help clarify the mechanism. Until those questions are answered, the reported results remain evidence of a consistent change in blood measures—not proof of a new anemia treatment effect.

Key Questions

How much did hemoglobin change in the analysis?

Hemoglobin rose by an average of 0.55 g/dL in SGLT2 inhibitor groups and fell by 0.08 g/dL in control groups over a median of 24 weeks. The reported between-group difference was 0.60 g/dL.

Did hematocrit also increase?

Yes. Hematocrit rose by 2.17% in treatment groups and declined by 0.13% in controls, for a reported between-group difference of 2.36 percentage points.

Does this prove SGLT2 inhibitors treat anemia?

No. The analysis found changes in blood measures and the editorial authors said those changes could contribute to anemia management. It did not establish that the drugs treat anemia or replace conventional anemia therapies.

Do researchers know why hemoglobin increased?

Not conclusively. Higher erythropoietin and changes in iron-related measures suggest the effect may involve red blood cell production and iron metabolism, but the trials lacked direct measurements such as red blood cell mass and plasma volume.

What safety concern did the report raise?

The authors cautioned that further increases could potentially raise thromboembolic risk among people with already elevated hemoglobin or hematocrit. The analysis did not quantify that risk or show that the observed increases caused such events.

Source: rss